Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AIO-Studien-gGmbH
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimidine and bevacizumab vs. bevacizumab alone vs. no maintenance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer
Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer af...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC
The primary objective is to investigate clinical efficacy of a nivolumab-radiotherapy combination treatment.. Das primäre Studienziel ist die Untersuchung der Wirksamkeit einer Kombination aus N...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
ECX + Panitumumab vs. ECX alone in subjects with locally advanced gastric cancer or cancer of the gastroesophageal junction
To compare prevalence of pT3/T4 categories (in reference to UICC 2002 criteria, Appendix F) between subjects receiving panitumumab plus epirubicin, cisplatin and capecitabine (ECX) versus subjects tre...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma
To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Étude MATEO : étude de phase 2 randomisée visant à évaluer l’efficacité relative en termes de survie globale de la thérapie de désescalade de S-1 (Teysuno®) à la continuation de la chimiothérapie après une thérapie d’induction chez des patients ayant un cancer métastatique de l’oesophage ou de la jonction gastro-oesophagienne ou de l’estomac. [essai clos aux inclusions]
Le cancer de l’estomac reste le deuxième cancer digestif en incidence en France avec environ 7000 nouveaux cas et 6000 décès par an. Son pronostic reste médiocre avec une survie globale à 10 ans d’env...
Country
France
organs
Estomac
,
Oesophage
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Therapy with gefitinib followed by conventional chemotherapy in certain tumor patients. Therapie mit Gefitinib gefolgt von einer konventionellen Chemotherapie in bestimmten Tumorpatienten
The primary objective of the study is to assess the pathologic complete remission rate (according to the Junker criteria regression IIB and III) after induction therapy with gefitinib D-12 to D -1 fol...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer
To assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
FOLFOXIRI with or without panitumumab in metastatic colorectal cancer
To assess efficacy (objective response rate, ORR) of adding panitumumab to FOLFOXIRI in patients with newly diagnosed metastatic colorectal cancer expressing wild-type RAS Cohort I) Definitively unr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Explorative trial to investigate catumaxomab (antibody) for treatment of peritoneal carcinomatosis in patients with gastric cancer prior to surgery (resection)
The main objective of this trial is to investigate the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cyc...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AIO-Studien-gGmbH
Update Il y a 4 ans
Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable adenocarcinoma of the gastroesophageal junction or stomach (HerFLOT) Multizentrische, Explorative Phase II Studie mit perioperativer Gabe von 5-FU, Leucovorin, Docetaxel und Oxaliplatin (FLOT) in Kombination mit Trastuzumab bei Patienten mit HER2-positivem, lokal fortgeschrittenem, resektablem Adenokarzinom des gastroösophagealen Übergangs oder des Magens
Primary objective of the study is to estimate the efficacy of the trastuzumab/FLOT combination consisting of 5-FU/leucovorin, oxaliplatin, docetaxel and the antibody in locoregional cancer of the stom...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
Next